Europe Liquid Biopsy For Early Cancer Detection And Monitoring Market Size & Outlook
Related Markets
Europe liquid biopsy for early cancer detection and monitoring market highlights
- The Europe liquid biopsy for early cancer detection and monitoring market generated a revenue of USD 589.1 million in 2024.
- The market is expected to grow at a CAGR of 11.3% from 2025 to 2033.
- In terms of segment, circulating tumor cells (ctcs) was the largest revenue generating biomarker in 2024.
- Exosomes/Microvesicles is the most lucrative biomarker segment registering the fastest growth during the forecast period.
- Country-wise, UK is expected to register the highest CAGR from 2025 to 2033.
Europe data book summary
| Market revenue in 2024 | USD 589.1 million |
| Market revenue in 2033 | USD 1,523.9 million |
| Growth rate | 11.3% (CAGR from 2025 to 2033) |
| Largest segment | Circulating tumor cells (ctcs) |
| Fastest growing segment | Exosomes/Microvesicles |
| Historical data covered | 2021 - 2023 |
| Base year for estimation | 2024 |
| Forecast period covered | 2025 - 2033 |
| Quantitative units | Revenue in USD million |
| Market segmentation | Circulating Tumor Cells (CTCs), Circulating Tumor DNA (ctDNA), Exosomes/Microvesicles, Circulating Proteins |
Other key industry trends
- In terms of revenue, Europe region accounted for 26.3% of the global liquid biopsy for early cancer detection and monitoring market in 2024.
- Globally, North America is projected to lead the regional market in terms of revenue in 2033.
- Asia Pacific is the fastest growing regional market and is projected to reach USD 1,523.7 million by 2033.
No credit card required*
Horizon in a snapshot
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
Liquid Biopsy for Early Cancer Detection and Monitoring Market Scope
Liquid Biopsy for Early Cancer Detection and Monitoring Market Companies
| Name | Profile | # Employees | HQ | Website |
|---|---|---|---|---|
| Grail | View profile | 1001-5000 | Menlo Park, California, United States, North America | https://www.grail.com |
| Elypta | View profile | 11-50 | Stockholm, Stockholms Lan, Sweden, Europe | https://www.elypta.com/ |
| GeneCast | View profile | 1-10 | Seoul, Seoul-t'ukpyolsi, South Korea, Asia | http://genecast.co.kr |
| AnchorDx | View profile | 51-100 | Guangzhou, Guangdong, China, Asia | http://www.anchordx.com/ |
| Burning Rock Biotech Ltd ADR | View profile | 786 | No. 5, Xingdao Ring Road North, International Bio Island, Guangzhou, China, People's Republic of, 510005 | https://www.brbiotech.com |
| Freenome | View profile | 501-1000 | South San Francisco, California, United States, North America | https://www.freenome.com |
| Oncimmune | View profile | 51-100 | Nottingham, Nottingham, United Kingdom, Europe | http://oncimmune.com/ |
| Lucence Health | View profile | 51-100 | Palo Alto, California, United States, North America | https://www.lucence.com/ |
| Exact Sciences Corp | View profile | 6600 | 5505 Endeavor Lane, Madison, WI, United States, 53719 | https://www.exactsciences.com |
| Guardant Health Inc | View profile | 1779 | 3100 Hanover Street, Palo Alto, CA, United States, 94304 | https://www.guardanthealth.com |
| Myriad Genetics Inc | View profile | 2700 | 320 Wakara Way, Salt Lake City, UT, United States, 84108 | https://www.myriad.com |
Europe liquid biopsy for early cancer detection and monitoring market outlook
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to liquid biopsy for early cancer detection and monitoring market will help companies and investors design strategic landscapes.
Circulating tumor cells (ctcs) was the largest segment with a revenue share of 34.39% in 2024. Horizon Databook has segmented the Europe liquid biopsy for early cancer detection and monitoring market based on circulating tumor cells (ctcs), circulating tumor dna (ctdna), exosomes/microvesicles, circulating proteins covering the revenue growth of each sub-segment from 2021 to 2033.
Reasons to subscribe to Europe liquid biopsy for early cancer detection and monitoring market databook:
-
Access to comprehensive data: Horizon Databook provides over 1 million market statistics and 20,000+ reports, offering extensive coverage across various industries and regions.
-
Informed decision making: Subscribers gain insights into market trends, customer preferences, and competitor strategies, empowering informed business decisions.
-
Cost-Effective solution: It's recognized as the world's most cost-effective market research database, offering high ROI through its vast repository of data and reports.
-
Customizable reports: Tailored reports and analytics allow companies to drill down into specific markets, demographics, or product segments, adapting to unique business needs.
-
Strategic advantage: By staying updated with the latest market intelligence, companies can stay ahead of competitors, anticipate industry shifts, and capitalize on emerging opportunities.
Target buyers of Europe liquid biopsy for early cancer detection and monitoring market databook
-
Our clientele includes a mix of liquid biopsy for early cancer detection and monitoring market companies, investment firms, advisory firms & academic institutions.
-
30% of our revenue is generated working with investment firms and helping them identify viable opportunity areas.
-
Approximately 65% of our revenue is generated working with competitive intelligence & market intelligence teams of market participants (manufacturers, service providers, etc.).
-
The rest of the revenue is generated working with academic and research not-for-profit institutes. We do our bit of pro-bono by working with these institutions at subsidized rates.
Horizon Databook provides a detailed overview of continent-level data and insights on the Europe liquid biopsy for early cancer detection and monitoring market , including forecasts for subscribers. This continent databook contains high-level insights into Europe liquid biopsy for early cancer detection and monitoring market from 2021 to 2033, including revenue numbers, major trends, and company profiles.
Partial client list
Europe liquid biopsy for early cancer detection and monitoring market size, by country, 2021-2033 (US$M)
Europe Liquid Biopsy for Early Cancer Detection and Monitoring Market Outlook Share, 2024 & 2033 (US$M)
Related industry reports
Related statistics
Sign up - it's easy, and free!
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account
- 30K+ Global Market Reports
- 120K+ Country Reports
- 1.2M+ Market Statistics
- 200K+ Company Profiles
- Industry insights and more
